Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 607-617

  Livaudais, Jennifer C ^a   Hershman, Dawn L ^b   Habel, Laurel ^c   Kushi, Lawrence ^c   Gomez, Scarlett Lin ^d   Li, Christopher I ^e,f   Neugut, Alfred I ^b   Fehrenbacher, Louis ^c   Thompson, Beti ^e,f   Coronado, Gloria D ^g  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c Kaiser Research Institute   (United States)

^d CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Adjuvant hormonal therapy; Aromatase inhibitors; Breast cancer; Racial ethnic disparities; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CAUCASIAN; CHINESE; DRUG USE; ETHNIC DIFFERENCE; FEMALE; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH INSURANCE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; ETHNIC GROUPS; FEMALE; HUMANS; MIDDLE AGED;

EID: 84856230195     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1762-1     Document Type: Article

References (38)

1. A Jemal, et al. 2004 Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival Cancer 101 1 3 27 15221985 10.1002/cncr.20288 (Pubitemid 38812419)
2. SS Lin, et al. 2002 Survival differences among Asian subpopulations in the United States after prostate, colorectal, breast, and cervical carcinomas Cancer 94 4 1175 1182 11920489 10.1002/cncr.10319 (Pubitemid 34150874)
3. SL Ooi ME Martinez CI Li 2011 Disparities in breast cancer characteristics and outcomes by race/ethnicity Breast Cancer Res Treat 127 3 729 738 21076864 10.1007/s10549-010-1191-6
4. M Banerjee, et al. 2007 Disentangling the effects of race on breast cancer treatment Cancer 110 10 2169 2177 17924374 10.1002/cncr.23026 (Pubitemid 350100737)
5. D Hershman, et al. 2005 Racial disparities in treatment and survival among women with early-stage breast cancer J Clin Oncol 23 27 6639 6646 16170171 10.1200/JCO.2005.12.633 (Pubitemid 46190258)
6. Clarke MJ (2008) Tamoxifen for early breast cancer. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000486
7. S Alkner, et al. 2009 Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial Eur J Cancer 45 14 2496 2502 19535242 10.1016/j.ejca.2009.05.022 1:CAS:528: DC%2BD1MXhtVKls7vP
8. DL Hershman T Shao LH Kushi D Buono WY Tsai L Fehrenbacher M Kwan SL Gomez AI Neugut 2011 Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer Breast Cancer Res Treat 126 2 529 537 20803066 10.1007/s10549-010-1132-4 1:CAS:528:DC%2BC3MXjtFSrtrw%3D
9. AW Prehn, et al. 2002 Differences in treatment patterns for localized breast carcinoma among Asian/Pacific islander women Cancer 95 11 2268 2275 12436431 10.1002/cncr.10965 (Pubitemid 35351131)
10. RA Freedman, et al. 2011 The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care Cancer 117 1 180 189 20939011 10.1002/cncr.25542
11. LJ Short, et al. 2010 Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention Cancer 116 1 193 202 19877115
12. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
13. NCCN Guidelines Version 2.2011:Breast Cancer 2011. http://www.nccn.com/ patient-guidelines.html. Accessed 16 May 2011
14. AK Fink, et al. 2004 Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer J Clin Oncol 22 16 3309 3315 15310774 10.1200/JCO.2004.11.064 (Pubitemid 41103687)
15. S Demissie RA Silliman TL Lash 2001 Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women J Clin Oncol 19 2 322 328 11208822 1:CAS:528:DC%2BD3MXhtVektrk%3D (Pubitemid 32112842)
16. KL Kahn, et al. 2007 Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use Med Care 45 5 431 439 17446829 10.1097/01.mlr.0000257193.10760.7f
17. TL Lash, et al. 2006 Adherence to tamoxifen over the five-year course Breast Cancer Res Treat 99 2 215 220 16541307 10.1007/s10549-006-9193-0 (Pubitemid 44268270)
18. C Owusu, et al. 2008 Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer J Clin Oncol 26 4 549 555 18071188 10.1200/JCO.2006.10.1022 (Pubitemid 351264347)
19. G Kimmick, et al. 2009 Adjuvant hormonal therapy use among insured, low-income women with breast cancer J Clin Oncol 27 21 3445 3451 19451445 10.1200/JCO.2008.19.2419
20. I Pellegrini A Sarradon-Eck PB Soussan AC Lacour R Largillier A Tallet C Tarpin C Julian-Reynier 2010 Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view Psychooncology 19 5 472 479 19507263 10.1002/pon.1593
21. DL Hershman, et al. 2010 Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients J Clin Oncol 28 27 4120 4128 20585090 10.1200/JCO.2009.25.9655
22. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114): 1451-1467
23. K Yost, et al. 2001 Socioeconomic status and breast cancer incidence in California for different race/ethnic groups Cancer Causes Control 12 8 703 711 11562110 10.1023/A:1011240019516 1:STN:280:DC%2BD3MrhsVantw%3D%3D (Pubitemid 32803497)
24. ME Charlson, et al. 1987 A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 5 373 383 3558716 10.1016/0021-9681(87)90171-8 1:STN:280:DyaL2s7ms1GnsQ%3D%3D (Pubitemid 17055592)
25. CN Klabunde, et al. 2000 Development of a comorbidity index using physician claims data J Clin Epidemiol 53 12 1258 1267 11146273 10.1016/S0895-4356(00)00256-0 1:STN:280:DC%2BD3M%2FptlSrtQ%3D%3D (Pubitemid 32007842)
26. NA Bickell, et al. 2006 Missed opportunities: racial disparities in adjuvant breast cancer treatment J Clin Oncol 24 9 1357 1362 16549830 10.1200/JCO.2005.04.5799 (Pubitemid 46621998)
27. KT Ashing-Giwa, et al. 2006 Understanding the breast cancer experience of Latina women J Psychosoc Oncol 24 3 19 52 17088240 10.1300/J077v24n03-02 (Pubitemid 44532904)
28. LP Buki, et al. 2008 Latina breast cancer survivors' lived experiences: diagnosis, treatment, and beyond Cultur Divers Ethnic Minor Psychol 14 2 163 167 18426289 10.1037/1099-9809.14.2.163 (Pubitemid 351636291)
29. AM Napoles-Springer, et al. 2007 Information exchange and decision making in the treatment of Latina and white women with ductal carcinoma in situ J Psychosoc Oncol 25 4 19 36 18032263 10.1300/J077v25n04-02 (Pubitemid 350166021)
30. Medline Plus Drug Information: Anastrozole (2008) http://www.nlm.nih.gov/ medlineplus/print/druginfo/medmaster/a696018.html. Accessed 1 July 2008
31. Medline Plus Drug Information: Tamoxifen (2008) http://www.nlm.nih.gov/ medlineplus/print/druginfo/medmaster/a682414.html. Accessed 1 July 2008
32. KT Ashing-Giwa, et al. 2004 Understanding the breast cancer experience of women: a qualitative study of African American, Asian American, Latina and Caucasian cancer survivors Psychooncology 13 6 408 428 15188447 10.1002/pon.750 (Pubitemid 38832606)
33. DJ Oates RA Silliman 2009 Health literacy: improving patient understanding Oncology (Williston Park) 23 4 376 379
34. E Maunsell, et al. 2005 Breast cancer survivors accurately reported key treatment and prognostic characteristics J Clin Epidemiol 58 4 364 369 15862722 10.1016/j.jclinepi.2004.09.005 (Pubitemid 40601984)
35. KA Phillips, et al. 2005 Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry J Clin Oncol 23 21 4679 4686 15851764 10.1200/JCO.2005.03.002 (Pubitemid 46224070)
36. XL Du, et al. 2006 Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews J Clin Epidemiol 59 1 53 60 16360561 10.1016/j.jclinepi.2005.06.002 (Pubitemid 41797475)
37. LX Clegg, et al. 2007 Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies Cancer Causes Control 18 2 177 187 17219013 10.1007/s10552-006-0089-4 (Pubitemid 46215314)
38. SL Gomez SL Glaser 2006 Misclassification of race/ethnicity in a population-based cancer registry (United States) Cancer Causes Control 17 6 771 781 16783605 10.1007/s10552-006-0013-y